Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The brain metastasis from differentiated thyroid carcinoma (DTC) is a rare condition and its prognosis is poor. The standard protocol for screening and treatment of patients with brain metastases from papillary thyroid cancer (PTC) remains controversial. This report aims to share the experience of a single center in the management of brain metastases from DTC.
Material And Methods: Five patients with brain metastases were identified from 5000 patients with DTC attending the department of nuclear medicine, Hospital 108 between 2016 to 2022. The statistical software Statistical Package for Social Sciences (SPSS) 20.0 (SPSS Inc., Chicago, IL, USA) was used to analyze the data.
Results: Five patients with brain metastases from DTC were revealed by MRI, F-FDG PET/CT with contrast enhancement, and I-SPECT/CT. The median time of overall survival (OS) was 15 months, ranging from 10 to 65 months. Two out of the five patients underwent surgery, and futher 2 patients were treated with stereotactic surgery (SRS). All patients are still alive.
Conclusions: Brain metastases from DTC are rare. MRI is the preferred imaging mobility to screen brain lesions in DTC. The primary treatment modalities are surgery and SRS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832656 | PMC |
| http://dx.doi.org/10.1186/s13044-023-00146-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer.
Breast Cancer Res Treat
September 2025
Department of Pharmacy, Duke University Hospital, Durham, NC, USA.
Purpose: Limited data is available assessing sequencing of antibody drug conjugates (ADCs) in patients with hormone receptor-positive (HR +), human epidermal growth factor 2 (HER2)-negative, HER2-low, and triple-negative metastatic breast cancer (MBC), including patients with brain metastases (BrM) or leptomeningeal disease (LMD). This study assesses the efficacy and safety of sequential sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) in MBC and impact on chemotherapy (CTX).
Methods: This is a single-center, retrospective, cohort study in adult patients with HR + , HER2-negative, or low MBC who received T-DXd and/or SG.
Wearable device-measured circadian rest-activity rhythm with mortality risk in patients with cancer.
BMJ Health Care Inform
September 2025
Center for Sleep and Circadian Medicine, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China
Objectives: The objectives were to examine the associations between accelerometer-measured circadian rest-activity rhythm (CRAR), the most prominent circadian rhythm in humans and the risk of mortality from all-cause, cancer and cardiovascular disease (CVD) in patients with cancer.
Methods: 7456 cancer participants from the UK Biobank were included. All participants wore accelerometers from 2013 to 2015 and were followed up until 24 January 2024, with a median follow-up of 9.
Intraoperative radiotherapy for resectable brain metastases: a systematic review and meta-analysis.
Radiother Oncol
September 2025
Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany; Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany. Electronic address:
Background: In recent years, intraoperative radiotherapy (IORT) with low-energy X-rays is emerging as an alternative to postoperative stereotactic radiotherapy (SRT) of the resection cavity in patients with resectable brain metastases (BMs).
Methods: We performed a systematic review of the MEDLINE, Embase, and Scopus databases, including all original articles on IORT for resectable BMs from 2015 to 2025. Data on safety, local control, and survival outcomes were collected.
Staged Gamma Knife radiosurgery for large brain metastases: Local control and the influence of systemic treatment.
Radiother Oncol
September 2025
Amsterdam UMC, Location University of Amsterdam, Department of Neurosurgery, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Neuroscience, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.
Background And Purpose: Staged Gamma Knife radiosurgery (SGKRS) delivers high-dose radiotherapy to large brain metastases (BM) in two or three fractions with a time interval of several weeks. Various systemic treatments have also demonstrated favorable intracranial responses. Therefore, the outcome of patients undergoing radiosurgery and systemic treatment for large BM is of high interest but unknown.
View Article and Find Full Text PDFPerturbing neural stem cell fate in glioblastoma heterogeneity and beyond.
Stem Cell Reports
September 2025
Laboratory of Neural Stem Cells and Functional Neurogenetics, Farmington, CT 06030, USA; Departments of Neuroscience, Neurology, Genetics and Genome Sciences, UConn Health, Farmington, CT 06030, USA. Electronic address:
Intratumoral heterogeneity in glioblastoma is thought to underlie its remarkable ability to recur and resist therapies. Its origins, however, remain unknown. In this issue, Liu et al.
View Article and Find Full Text PDF